anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Falls are one of the leading causes of increased morbidity and mortality in the elderly population and are substantial contributor to increase healthcare cost burden. Pain, strength deficits, knee joint deformities, balance and proprioceptive impairments associated with severe knee OA, contribute to an increased risk of falling among elderly, and more than 50% of this population experience a fall each year. Static or dynamic postural control cannot be fully restored in patients with Total Knee Arthroplasty (TKA). Moreover, deficits in balance and postural control may still be present in both extremity after TKA. Increased weight-bearing on the operative side after TKA and reduced weight-bearing weight in the contralateral osteoarthritic knee can reduce pain and improve balance-related functions. However, the contralateral knee OA grade, asymmetrical gait pattern, and postural sways still remain a risk factor for balance deficits and falls. Based on this rationale, the aim of this study is to evaluate the balance and fall risk before and after TKA in patients who suffered from bilateral knee osteoarthritis and to clarify the balance and fall risk difference between unilateral and bilateral TKA patients.
Arm A: Pemetrexed, cisplatin: pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days. Patients will be treated for a maximum of 6 cycles.
Diabetes mellitus (DM) has become a global epidemic. Its complications can have a significant impact on quality of life, longevity, and costs in public health. The World Health Organization (WHO) estimates that by 2030, 439 million people will suffer from diabetes, around 10% of the world adult population (WHO, 2011). Periodontal Diseases are considered the sixth complication of DM. This close relationship between both diseases is characterized by mutual influence. Thus, an appropriate control of periodontal disease may facilitate the DM control, improving quality of life on diabetes patients. Besides that, the presence of DM might impair prognosis of diverse dental treatments due to its inflammatory nature, negative influence on wound healing, on bone biology, and the establishment of infections. Consequently, knowledge of new dental therapies and the biology of dental treatments for chronic periodontitis in diabetic patients can enhance quality of life and make these treatments more adequate for this common profile of patients. Therefore, the aim of the present study is to investigate the effectiveness of antimicrobial photodynamic therapy as adjunct to full-mouth debridement for the treatment of periodontitis in type 2 diabetic patients through a split-mouth randomized triple-blind clinical trial.
Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
Transnasal SPGB was performed by a single pain clinician. The posture was the same as that in the drip method. A cotton tip applicator soaked with 2% mepivacaine was inserted vertically into the nostril. After the cotton tip applicator made contact with the posterior wall of the middle turbinate, the cotton tip applicator was fixed for 10 min. A cotton tip applicator was inserted into the nostril, where the pain was dominant. In cases of bilateral pain, two applicators were inserted into both nostrils.
Understanding the intricate pathogenic mechanisms behind Parkinson's disease (PD) and its multifactorial nature presents a significant challenge in disease modeling. To address this, we explore genetic models that better capture the disease's complexity. Given that aging is the primary risk factor for PD, this study investigates the impact of aging in conjunction with overexpression of wild-type human α-synuclein (α-Syn) in the dopaminergic system. This is achieved by introducing a novel transgenic mouse strain overexpressing α-Syn under the TH-promoter within the senescence-accelerated SAMP8 (P8) genetic background. Behavioral assessments, conducted at both 10 and 16 months of age, unveil motor impairments exclusive to P8 α-SynTg mice, a phenomenon conspicuously absent in α-SynTg mice. These findings suggest a synergistic interplay between heightened α-Syn levels and the aging process, resulting in motor deficits. These motor disturbances correlate with reduced dopamine (DA) levels, increased DA turnover, synaptic terminal loss, and notably, the depletion of dopaminergic neurons in the substantia nigra and noradrenergic neurons in the locus coeruleus. Furthermore, P8 α-SynTg mice exhibit alterations in gut transit time, mirroring early PD symptoms. In summary, P8 α-SynTg mice effectively replicate parkinsonian phenotypes by combining α-Syn transgene expression with accelerated aging. This model offers valuable insights into the understanding of PD and serves as a valuable platform for further research.
Title compsns. which inhibit the prodn. of sebum by: sebaceous glands, comprise a pharmaceutically acceptable vehicle, and an effective quantity of a cpd of formula (I) (where R is H or 1-3C alkyl) or its salt with a pharmaceutically acceptable metal. They are used in the treatment of acne, and are applied topically in the form of gels, creams, lotions, aerosol foams etc. contg. 2-25 wt.% of the active ingredient. The prefd. cpds. have R = H or CH3.
OBJECTIVES: Alveolar echinococcosis (AE) represents one of the deadliest helminthic infections, characterized by an insidious onset and high lethality.
METHODS: This study utilized the Gene Expression Omnibus (GEO) database, applied Weighted Correlation Network Analysis (WGCNA) and Differential Expression Analysis (DEA), and employed the Matthews Correlation Coefficient (MCC) to identify CCL17 and CCL19 as key genes in AE. Immunohistochemistry and immunofluorescence co-localization techniques were used to examine the expression of CCL17 and CCL19 in liver tissue lesions of AE patients. Additionally, a mouse model of multilocular echinococcus larvae infection was developed to study the temporal expression patterns of these genes, along with liver fibrosis and inflammatory responses.
RESULTS: The in vitro model simulating echinococcal larva infection mirrored the hepatic microenvironment post-infection with multilocular echinococcal tapeworms. Quantitative RT-PCR analysis showed that liver fibrosis occurred in AE patients, with proximal activation and increased expression of CCL17 and CCL19 over time post-infection. Notably, expression peaked during the late stages of infection. Similarly, F4/80, a macrophage marker, exhibited corresponding trends in expression. Upon stimulation of normal hepatocytes by vesicular larvae in cellular experiments, there was a significant increase in CCL17 and CCL19 expression at 12 h post-infection, mirroring the upregulation observed with F4/80.
CONCLUSION: CCL17 and CCL19 facilitate macrophage aggregation via the chemokine pathway and their increased expression correlates with the progression of infection, suggesting their potential as biomarkers for AE progression.
Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
The recommended adult dose of Technetium Tc 99m-labeled Technescan HDP is 555 MBq (15 mCi) with a range of 370 to 740 MBq (10 to 20 mCi). The recommended pediatric dose is 7.4 MBq (0.20 mCi)/kg with a range of 7.4 to 13 MBq (0.20 to 0.35 mCi)/kg. The recommended minimum total pediatric dose is 37 MBq (1.0 mCi). The maximum total dose injected into a pediatric or adult patient is 740 MBq (20.0 mCi). The maximum dose of oxidronate sodium should not exceed 2 mg.

Unit dose preparation instructions should be followed for pediatric patients. The radioactivity of each dose should be measured by a suitable radiation calibration system just prior to administration. The dose should be given intravenously by slow injection. For optimal results imaging should be performed 1 to 4 hours post-injection.
Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigator"s discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course.
A method of producing a postbiotic comprising: (a) obtaining liquid pot ale from whisky production in the absence of enzymes; (b) concentrating the pot ale by reverse osmosis with 0.0002 micron or less pore size membrane to produce a fermentation medium; (c) inoculating the fermentation medium with probiotic bacteria, yeast, and/or fungus; (d) incubating; and (e) raising the temperature of the incubated pot ale to a temperature to kill the probiotic bacteria/yeast/fungus. The pot ale may be clarified before step (b) by mixing with aqueous carrageenan, centrifugation, or whirlpooling. The probiotic bacteria/yeast/fungus may be selected from Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus brevis, Paediococcus acidilactici, Saccharomyces cerevisiae, Aspergillus oryzae, Corynebacterium glutamicum, Propionibacterium acidipropionici. Salts, surfactants, nitrogen sources, seaweed filter cake, yeast extract, and protein hydrolysate (e.g. from chickpea, fava bean, or lentil protein concentrate) may be added to the fermentation medium. Step (d) may be primary or submerged fermentation. The postbiotic may be mixed with additional products, such as Aquamin, milled seaweed, foodstuff, or animal feed. The postbiotic product may have immunomodulatory properties e.g. increasing IL10 levels and decreasing TNFα levels.
Direct immersion solid-phase microextraction coupled with gas chromatography-mass spectroscopy was used to create chemical fingerprints of annual ryegrass cultivars (Lolium rigidum). Extracts made of the inflorescences of four cultivars and one accession of annual ryegrass were assessed to identify differential metabolites between those resistant to and susceptible to bacterial galls associated with annual ryegrass toxicity (ARGT). Numerous compounds were identified. Principal component analysis showed distinct clustering of metabolites from disease-resistant and disease-susceptible cultivars. Partial least-squares-discriminant analysis identified sterols, esters, aldehydes, and terpenes that correlated with resistance to galls formation. Esters, sterols, phenols, heterocyclics, fatty acids, organofluorides, and siloxanes were predominant in resistant genotypes, whereas alcohols, aldehydes, terpenes, and hydrocarbons were predominant in susceptible genotypes. The identification of differentially expressed metabolites provides potential chemical markers to guide breeding strategies for ARGT resistance in ryegrass.
Disclosed herein are biomarkers related to the identification or diagnosis of Parkinson's disease in a subject. The disclosed biomarkers and related methods are used to detect or predict Parkinson's disease status in a subject. The disclosed biomarkers and methods can be utilized to determine nature of Parkinson's disease, progression, or responsiveness to a treatment or prophylaxis. Some embodiments include methods of detecting the presence of a biomarker associated with a patient. Some embodiments of the methods include generating a report for clinical disease evaluation or management.  Some embodiments of the compositions include associated kits, peptides, binding members, and uses thereof. Also provided are methods and compositions for diagnosing, preventing, and treating Parkinson's disease in a subject in need thereof.
Patients wear an activity monitor throughout and up 4 weeks after completion of radiation therapy. Patients who are willing may continue to wear the monitor through routine follow up appointments. Patients also complete questionnaires at evaluations, which take place prior to radiotherapy initiation, weekly during radiotherapy, and then 2 and 4 weeks after the completion of radiotherapy.
Patients receive 1 cycle of cisplatin and nab paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of camrelizumab combined neoadjuvant chemotherapy. Based on the tumor size as indicated by MRI, patients who achieve complete response or partial response (CR/PR，RECIST v1.1) will undergo open radical hysterectomy and pelvic lymph node dissection. Patients who show stable disease or progression (SD/PD，v1.1) will proceed directly to concurrent chemoradiotherapy (CCRT).
Participants will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information and SMS reminders same as those of "scheduled SMS arm" above + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for the study participant they are supporting for all the study follow-up period (also called the "social support engagement arm"). Social supporters will be able to personalize the SMS content at enrollment. They will be advised to assist study participants with any problems that may affect ANC attendance or facility delivery, but will not be given specific instructions on what to do.
AIM: Methylation status of genome varies between pre-acute-on-chronic hepatitis B liver failure (pre-ACHBLF), acute-on-chronic hepatitis B liver failure (ACHBLF), and chronic hepatitis B patients. This study aimed to find better prognostic indicators for acute-on-chronic liver failure.
METHODS: The level of global genome methylation in peripheral blood mononuclear cells (PBMCs) was detected. The overall genome methylation rate was determined using MethylFlash™ Methylated DNA Quantification Kit(Colorimetric). DNMT activity were measured using DNA Methyltransferase Activity/Inhibition Assay Kit. Gene expression of DNA methyltransferases (DNMT),methyl-CpG-binding domain (MBD) were detected by qRT-PCR.
RESULTS: The global genome methylation level in ACHBLF group was significantly higher than that in chronic hepatitis B group (P<0.001). There was also obvious difference of the global genome methylation level between pre-ACHBLF group and CHB group (P<0.001). Meanwhile, the activity of DNMT in ACHBLF group was significantly higher than that in chronic hepatitis B group (P<0.001). The mRNA expression level of DNMT1 was higher than that in pre-ACHBLF group (P<0.01) and CHB group (PP<0.001). The mRNA expression level of MBD1 in ACHBLF group was also higher than that in CHB group (P<0.001) and healthy controls (HCs) (P<0.01). And the mRNA expression level of MBD3 and MBD4 in ACHBLF, pre-ACHBLF and CHB group were lower than that in HCs (P<0.001). Meanwhile we observed an opposite change in the mRNA expression level of MECP2. The ROC curve suggested that global genome methylation level was a better prognostic predictor than MELD score in ACHBLF (AUC 0.950, SE 0.0237, 95%CI 0.874-0.986 VS AUC 0.863, SE 0.0439, 95%CI 0.765-0.931, P=0.0429).
CONCLUSIONS: Genome methylation level can be a good biomarker in predicting the severity and prognosis of ACHBLF.
<P>PROBLEM TO BE SOLVED: To obtain a blood sugar level regulator and a therapeutic agent for diabetes comprising an enzymically treated pharmaceutical preparation [ABPC (Agaricus Blazei Practical Compound)] of the Agaricus Blazei.  <P>SOLUTION: This blood sugar level regulator is characterized by comprising Agaricus Blazei. The blood sugar level regulator and a therapeutic agent for the diabetes recovering diabetic phagocytic dysfunctions which comprise the Agaricus Blazei are provided. The Agaricus Blazei is useful for treating the diabetes, e.g. normalization of the blood sugar level, an improvement in phagocytic immune functions and an improvement in humoral immune functions.  <P>COPYRIGHT: (C)2004,JPO
The main reproductive problems associated with these malformations include, abortion , recurrent abortion ectopic pregnancy and preterm delivery . The experience gained from oocyte donation shows that these women are pregnant less, even with the transfer of good quality embryos. The hypothesis of this poor uterine receptivity is in the poor endometrial vascularization that can decrease embryo implantation. The reason for infertility in women with AM includes decreased muscle mass, decreased endometrial vascularization, decreased capacity of the endometrial cavity, less receptive areas (septum). The lower fertility observed in some women with Müllerian malformations has been partially explained by its tubal factor and its association with endometriosis, with a higher prevalence in them, compared to patients without malformations.

Studies have confirmed an irregular differentiation and estrogenic maturation of the endometrium lining the uterine septum or its internal structure, which has less presence of connective tissue and more muscle mass. Given the confusion generated if the unfavorable reproductive result is due to oocyte quality or endometrial receptivity, it is necessary to use a model that guarantees oocyte / embryo quality and this is offered by oocyte donation. The aim is to evaluate the implantation rate in women with MA who receive donated oocytes compared to women without MA.
The invention encompasses radiopharmaceutical compounds that can be used in imaging cell death associated with either apoptosis or necrosis. Phosphatidylethanolamine (PtdE) is externalized to the surface of apoptotic cells, and also becomes accessible in necrotic cells due to compromised plasma membrane integrity. Duramycin, a 19 amino acid polypeptide, binds PtdE at a 1:1 ratio with high affinity and exclusive specificity. Novel Duramycin-based radiopharmaceuticals and non-radioactively labeled compounds are disclosed herein. Such compounds facilitate detection of cell apoptosis and/or necrosis by binding to PtdE. The location of the bound compound can then be pinpointed using standard imaging techniques.
FIELD: medicine, veterinary science, pharmacy. SUBSTANCE: invention relates to synthetic peptide of the formula Arg-Tyr-D-Ala-Phe-Gly used as an adaptogen stress-correcting agent. Pharmaceutical composition based on a mixture of dimethylsulfoxide and polyethylene oxide-400 (or dimethylsulfoxide and olive oil) containing from 1 to 1000 mcg of synthetic peptide per 1 kg of animal body mass shows effective protective action against physical, emotional and chemical factors of environment. Preparation can be used by parenteral route. EFFECT: enhanced effectiveness of preparation, absence of toxicity. 2 cl, 6 tbl, 6 ex
Postnatal critical periods of synaptic plasticity (CPsp) are characterized by profound neural network refinement, which is shaped by synaptic activity and sculpted by maturation of the GABAergic network. Even after therapeutic hypothermia (TH), neonatal hypoxia-ischemia (HI) impairs two triggers for the initiation of the CPsp in the hippocampus: i) PSA-NCAM developmental decline and ii) parvalbumin (PV) + interneuron (IN) maturation. Thus, we investigated whether neonatal HI despite TH disturbs other events governing the onset, consolidation and closure of the postnatal CPsp in the hippocampus. We induced cerebral HI in P10 C57BL6 mice with right carotid ligation and 45 m of hypoxia (FiO2 = 0.08), followed by normothermia (36 °C, NT) or TH (31 °C) for 4 h with anesthesia-exposed shams as controls. ELISA, immunoblotting and immunohistochemistry were performed at 24 h (P11), 5 days (P15), 8 days (P18) and 30 days (P40) after HI injury. We specifically assessed: i) BDNF levels and TrkB activation, controlling the CPsp, ii) Otx2 and NPTX2 immunoreactivity (IR), engaging CPsp onset and iii) NogoR1, Lynx1 IR, PNN formation and myelination (MBP) mediating CPsp closure. Pups aged to P40 also received a battery of tests assessing working memory. Here, we documented deficits in hippocampal BDNF levels and TrkB activation at P18 in response to neonatal HI even with TH. Neonatal HI impaired in the CA1 the developmental increase in PV, Otx2, and NPTX2 between P11 and P18, the colocalization of Otx2 and PV at P18 and P40, the accumulation of NPTX2 in PV+ dendrites at P18 and P40, and the expression of NogoR at P40. Furthermore, neonatal HI decreased BDNF and impaired PNN development and myelination (MBP) at P40. Most of these abnormalities were insensitive to TH and correlated with memory deficits. Neonatal HI appears to disrupt many of the molecular and structural events initiating and consolidating the postnatal hippocampal CPsp, perhaps due to the early and delayed deficits in TrkB activation leading to memory deficits.
Cough is a common symptom of respiratory diseases and helps to clear respiratory secretions and harmful factors, but frequent severe coughing has a serious impact on the patient's work, life and social activities. Upper respiratory tract viral infection is a common cause of coughing. Many patients have a long duration of cough after suffering from flu. Cough can last for several weeks, and most often have irritating dry cough or a small amount of white mucus sputum. This type of cough is also often referred to as "subacute cough" or "post-infection cough." The mechanisms that cause this cough have not been fully elucidated, and the effect of conventional treatment is not good, and chest imaging has no obvious abnormalities. The use of large amounts of antibiotics is ineffective or ineffective. Antihistamine H1 receptor antagonists and central antitussives are often only effective or ineffective in the short term. The effects of various bronchodilators and even hormone drugs are not clear. Due to the poor efficacy of multiple treatments, patients are repeatedly subjected to various tests, which not only increases the pain but also aggravates the economic burden.

Therefore, it is necessary to further clarify the causes and treatment measures of post-influenza cough patients.
The present invention relates to antiaging health-care food, more specifically to a life prolonging and youth preserving capsule comprising goat placenta and fomes japonica, which is used for delaying aging and improving aging symptoms, such as immune functions, physiological functions, eyesight, audition, remembrance, old appearances, walking states, etc. for aging people. The present invention is characterized in that the capsule comprises 10 raw material components of percentage content by weight: 25 % of goat placenta, 15% of ganoderma, 5% of rhiizoma dioscoreae from Hena of China, 6% of barbary wolfberry fruit, 6% of silkworm chrysalis, 8% of fleeceflower root, 5% of semen sesami, 13% of fresh rehmannia, 12% of american ginseng and 5% of milkvetch root. The present invention combines the traditional Chinese medicine science and the modern medicine science together, and has religious formulation. The ten medicines are all products both are medicines and food, and have no toxic or side effect. The present invention gives attention to all aspects, and has comprehensive consideration, plenitudinous varieties and plenitudinous content. All the varieties supplement each other, so the present invention has high efficiency. When taken, the present invention has no contraindication, dispenses with diagnosis, cure or guidance, and is taken with water.
FIELD: medicine, surgery. SUBSTANCE: repeated percutaneous punctures of abscesses should be carried out. Exudate should be evacuated and washed with either an antiseptic solution or an antibiotic one. After each washing the cavity should be filled with an antiseptic or antibiotic solution up to 80% against the volume of evacuated exudate. EFFECT: higher efficiency of therapy. 3 dwg, 2 ex